- Home
- TVTX vs MKTX Comparison
TVTX vs MKTX Comparison
Compare TVTX & MKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TVTX | MKTX |
|---|---|---|
| Founded | N/A | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Bankers/Brokers/Service |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.3B | 4.6B |
| IPO Year | 2013 | 2004 |
Fundamental Metrics
Financial Performance| Metric | TVTX | MKTX |
|---|---|---|
| Price | $65.28 | $163.50 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 13 | 9 |
| Target Price | $40.62 | ★ $204.88 |
| AVG Volume (30 Days) | ★ 1.2M | 991.4K |
| Earning Date | 05-04-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 1.94% |
| EPS Growth | ★ 92.89 | N/A |
| EPS | N/A | ★ 4.13 |
| Revenue | N/A | ★ $397,471,000.00 |
| Revenue This Year | $44.76 | $10.14 |
| Revenue Next Year | $35.51 | $7.22 |
| P/E Ratio | ★ N/A | $39.56 |
| Revenue Growth | N/A | ★ 7.45 |
| 52 Week Low | $22.06 | $108.75 |
| 52 Week High | $68.03 | $195.97 |
Technical Indicators
Market Signals| Indicator | TVTX | MKTX |
|---|---|---|
| Relative Strength Index (RSI) | 60.45 | 81.66 |
| Support Level | $53.76 | $163.18 |
| Resistance Level | $66.24 | $163.94 |
| Average True Range (ATR) | 1.98 | 0.33 |
| MACD | -0.14 | -1.48 |
| Stochastic Oscillator | 71.85 | 97.92 |
Price Performance
Historical ComparisonAbout TVTX Travere Therapeutics Inc.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.
About MKTX MarketAxess Holdings Inc.
Founded in 2000, MarketAxess is a leading electronic fixed-income trading platform that connects broker/dealers and institutional investors. The company is primarily focused on credit based fixed income securities with its main trading products being US investment-grade and high-yield bonds, Eurobonds, and Emerging Market corporate debt. Recently the company has expanded more aggressively into Treasuries and municipal bonds with the acquisitions of LiquidityEdge and MuniBrokers in 2019 and 2021, respectively. The company also provides pre- and post-trade services with its acquisition of Regulatory Reporting Hub from Deutsche Börse Group in 2020 adding to its product offerings.